Detailing Biowarfare: Deceptive Medicine

Deceptive medical practice: using the wrong terminology to get the public to accept your "public health intervention" aka military countermeasure. David Martin holds the receipts that show what is meant by "big pharma crimes".

Moderna's SEC filing states:
Currently, mRNA is considered a gene therapy product by the FDA. Unlike certain gene therapies that irreversibly alter cell DNA and could act as a source of side effects, mRNA-based medicines are designed to not irreversibly change cell DNA; however, side effects observed in gene therapy could negatively impact the perception of mRNA medicines despite the differences in mechanism. In addition, because no product in which mRNA is the primary active ingredient has been approved, the regulatory pathway for approval is uncertain. The number and design of the clinical trials and preclinical studies required for the approval of these types of medicines have not been established, may be different from those required for gene therapy products, or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one pharmaceutical product to the next, and may be difficult to predict.
*We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.
https://www.sec.gov/Archives/edgar/data/1682852/000168285220000017/mrna-20200630.htm

Learn more about Moderna's near-bankruptcy until covid came along at:
https://unlimitedhangout.com/modernas-hail-mary/

BioNTech's SEC filing:
"We are a clinical-stage biopharmaceutical company with no pharmaceutical products approved for commercial sale."

"No mRNA immunotherapy has been approved, and none may ever be approved, in this new potential category of therapeutics. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of therapeutics."

"To our knowledge, there is no current precedent for an mRNA-based immunotherapy such as the type we are developing being approved for sale by the FDA, European Commission or any other regulatory agency elsewhere in the world."
https://www.sec.gov/Archives/edgar/data/1776985/000119312520022991/d838504df1.htm

VIDEO SOURCE: https://rumble.com/v6c1dn1-graham-and-john-speak-in-this-part-interview-with-dr-david-martin.html?e9s=src_v1_upp